Phase II Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Ponatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Filgrastim; Mesna; Methotrexate; Methotrexate; Rituximab; Vincristine
- Indications Acute lymphoblastic leukaemia
- Focus Therapeutic Use
- 07 Sep 2017 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.
- 07 Sep 2017 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2023.
- 07 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.